IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

-					_
In	re	app	lica	tion	of:

Chamberlain, et al.

International App. No.:

PCT/US03/06022

Group Art Unit:

International Filing Date: February 28, 2003

Examiner:

For:

DIAMINO-PYRIMIDINES AND THEIR USE AS ANGIOGENESIS INHIBITORS

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Exa		cants request that the references identified on Form PTO-1449 appended hereto be considered by the nd officially made of record in accordance with the provisions of 37 CFR 1.97
	[] Co [X] A p(ar	opies of the references are enclosed opies of the references were submitted in parent application Serial No (37 CFR 1.98(d)) copy of the International Search Report which issued on International Application No T/US03/06022 is submitted herewith. All of the publications cited in the International Search Report e listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the S. Patent Office by the International Bureau.
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
	OR	
	[]	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
В.	[] .	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, nichever occurs first.
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$240.00).

C.	f 1	The Information Disclosure Statement transmitted herewith is being filed after a final action under §
		1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the
		issue fee. Also enclosed is a copy of the International Search Report which Issued on International
		Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [] A duplicate copy of this paper is attached.

Respectfully Submitted,

Jennifer L. Fox

Agent for Appliant

Registration No. 52,218

Date: L Supt of GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-6334 Facsimile: (919) 483-7988

1 0 / 506 4 47 DT05 HDd PCT/PT0 0 1 SEP 2004

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT			ATTORNEY DOCKET INTERNATIONAL APP. NO. PCT/US03/06022 APPLICANT			IONAL		
				Chamberlain et al. INTERNATIONAL FILING DATE		GROUP		
- -			II S P	ATENT D	2/28/03 OCUMENTS			
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate
	J	1	Co	ontinue on j	nage		<u> </u>	<u> </u>
					T DOCUMENTS			
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes No
	1	07/19065	5/29/97	PCT				
	2	00/12089	3/9/00	PCT				
-	3	02/59110	8/1/02	PCT			 	
· · · · · ·							 	
		<u> </u>		ontinue on			<u> </u>	<u> </u>
	O'	THER DOCUMI	ENTS (Includir	ng Author,	Title, Journal-D	ate, Page Nu	mber, Etc.)	
	1							
	+							
	+							
					-			
	 							
	+					·		
	+							
	ļ							
	1	1		ontinuo on	2000			
EXAMINE	FR .			ontinue on	page	DATE	CONSIDERED)
771 HAIII 41	-41			_				
EXAMINE through cit applicant.	ER: In	itial if citation co if not in conforma	nsidered, wheth nce and not cor	er or not ci	tation is in confor aclude copy of this	mance with I s form with n	MPEP § 609; Dext communication	Draw line ation to the